23 Jul, 2026
According to Straits Research, the global cell therapy raw materials market was valued at USD 5.34 billion in 2025 and is projected to grow from USD 6.29 billion in 2026 to USD 23.96 billion by 2034, registering a CAGR of 18.18% during the forecast period (2026–2034).
The market is growing rapidly due to the increasing development of cell therapies, expanding clinical trials, and rising demand for GMP-grade raw materials used in advanced biopharmaceutical manufacturing.
Cell therapy raw materials are the essential products used to develop, manufacture, and preserve therapeutic cells for medical treatments. These materials include cell culture media, sera, cell culture supplements, antibodies, reagents, buffers, and other specialized components that support cell growth, expansion, modification, and storage.
The global cell therapy raw materials market is experiencing strong growth as regenerative medicine becomes one of the fastest-growing areas in healthcare. Pharmaceutical and biotechnology companies are increasing investments in cell-based therapies to treat cancer, autoimmune diseases, rare genetic disorders, and other chronic medical conditions.
One of the primary drivers of market growth is the rising number of clinical trials for cell therapies. As more therapies progress from research laboratories to commercial manufacturing, demand for standardized and high-quality raw materials continues to increase. Manufacturers require reliable media, supplements, antibodies, and reagents that meet strict regulatory standards while ensuring consistent product quality.
The growing adoption of personalized medicine is also supporting market expansion. Autologous and allogeneic cell therapies require specialized manufacturing processes that depend on premium-grade raw materials capable of maintaining cell viability and therapeutic effectiveness.
North America dominates the global market due to its advanced biotechnology industry, large number of cell therapy developers, strong research infrastructure, and significant investments in regenerative medicine.
Asia-Pacific is expected to witness the fastest growth during the forecast period as countries such as China, Japan, South Korea, and India continue expanding their biotechnology manufacturing capabilities and research activities.
sales@straitsresearch.com